000304845 001__ 304845 000304845 005__ 20250925115117.0 000304845 0247_ $$2doi$$a10.1002/bco2.70081 000304845 0247_ $$2pmid$$apmid:40979549 000304845 0247_ $$2pmc$$apmc:PMC12446083 000304845 037__ $$aDKFZ-2025-01951 000304845 041__ $$aEnglish 000304845 082__ $$a610 000304845 1001_ $$00000-0001-8085-0555$$aHaider, Muhammad$$b0 000304845 245__ $$aEmerging tools for the early detection of prostate cancer. 000304845 260__ $$a[Hoboken, NJ]$$bWiley$$c2025 000304845 3367_ $$2DRIVER$$aarticle 000304845 3367_ $$2DataCite$$aOutput Types/Journal article 000304845 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1758723416_30917$$xReview Article 000304845 3367_ $$2BibTeX$$aARTICLE 000304845 3367_ $$2ORCID$$aJOURNAL_ARTICLE 000304845 3367_ $$00$$2EndNote$$aJournal Article 000304845 520__ $$aProstate cancer (PCa) is the second most common cancer in men globally, with a rising incidence. Early detection through population-based screening by Prostate Specific Antigen (PSA) testing improves survival outcomes, at the expense of overdiagnosis and overtreatment of clinically insignificant disease. Here, we explore emerging tools for more effective PCa early detection and evaluate their potential roles for PCa screening.Key articles on emerging adjuncts and alternatives to PSA for PCa early detection were identified.Multiparametric MRI (mpMRI) remains the gold standard modality for identifying clinically significant PCa and has been evaluated for screening. Newer imaging strategies incorporating biparametric MRI (bpMRI) or multiparametric ultrasound (mpUS) potentially offer similar accuracy to mpMRI. Saliva-derived polygenic risk scores (PRS) hold potential as a non-invasive screening tool to identify at-risk patient groups. Blood-based biomarker tests can improve risk stratification, reducing unnecessary biopsies while maintaining detection of clinically significant cancers compared to PSA alone. Urine-based biomarker tests have been examined for the early detection and risk stratification of clinically significant disease as adjuncts to PSA testing.PSA is commonly used to detect early PCa, but its lack of specificity and associated overdiagnosis risk has led to controversy over its use for population-based screening. Imaging modalities such as mpMRI have reduced detection of clinically insignificant PCa, and emerging cost-effective alternatives, such as bpMRI and mpUS, show promise. Molecular biomarkers and PRS for risk stratification may help target imaging-based early detection more effectively to at-risk populations. Prospective randomised clinical trials are urgently needed to evaluate the performance of different modalities for population-wide screening. Future developments may involve technologies such as artificial intelligence and diagnostic tests that incorporate circulating tumour markers. 000304845 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0 000304845 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de 000304845 650_7 $$2Other$$a4 K score 000304845 650_7 $$2Other$$aAI 000304845 650_7 $$2Other$$aExoDx prostate 000304845 650_7 $$2Other$$aMRI 000304845 650_7 $$2Other$$aMyProstateScore 000304845 650_7 $$2Other$$aPRS 000304845 650_7 $$2Other$$aPSA 000304845 650_7 $$2Other$$aSelectMDx 000304845 650_7 $$2Other$$aStockholm 3 000304845 650_7 $$2Other$$aearly diagnosis 000304845 650_7 $$2Other$$apolygenic risk score 000304845 650_7 $$2Other$$aprostate cancer 000304845 650_7 $$2Other$$aprostate health index 000304845 650_7 $$2Other$$ascreening 000304845 650_7 $$2Other$$aultrasound 000304845 7001_ $$aLeow, Jeffrey J$$b1 000304845 7001_ $$00000-0003-4915-7546$$aNordström, Tobias$$b2 000304845 7001_ $$aMortezavi, Ashkan$$b3 000304845 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b4$$udkfz 000304845 7001_ $$aHeer, Rakesh$$b5 000304845 7001_ $$00000-0001-8064-9878$$aRajan, Prabhakar$$b6 000304845 773__ $$0PERI:(DE-600)3015455-8$$a10.1002/bco2.70081$$gVol. 6, no. 9, p. e70081$$n9$$pe70081$$tBJUI compass$$v6$$x2688-4526$$y2025 000304845 909CO $$ooai:inrepo02.dkfz.de:304845$$pVDB 000304845 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ 000304845 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0 000304845 9141_ $$y2025 000304845 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-07$$wger 000304845 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07 000304845 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07 000304845 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:09:29Z 000304845 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:09:29Z 000304845 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2024-08-08T17:09:29Z 000304845 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-08T17:09:29Z 000304845 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07 000304845 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2025-01-07 000304845 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07 000304845 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07 000304845 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07 000304845 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0 000304845 980__ $$ajournal 000304845 980__ $$aVDB 000304845 980__ $$aI:(DE-He78)C130-20160331 000304845 980__ $$aUNRESTRICTED